Go Pro
→ #1 Stock to Own as Trump Launches Historic Mission Backing 'Medical AI' (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$9.06
+0.6%		$8.62
$6.01
▼
$17.44
$84.82M1.694,377 shs111,553 shs
AlloVir, Inc. stock logo
ALVR
AlloVir
$4.03
-1.7%		$4.19
$7.96
▼
$24.15
$20.32M0.6315,685 shs52,613 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.67
+7.7%		$1.56
$1.34
▼
$3.20
$87.64M0.0467,500 shs135,390 shs
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
$1.14
-4.2%		$1.18
$0.89
▼
$2.09
$78.40M-0.2454,854 shs36,957 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
0.00%-1.41%0.00%-2.69%-25.06%
AlloVir, Inc. stock logo
ALVR
AlloVir
-1.71%-2.89%+18.53%-23.53%+57.42%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%+8.44%+0.60%-2.62%-26.11%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
0.00%+0.88%-8.80%-12.31%-22.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$9.06
+0.6%		$8.62
$6.01
▼
$17.44
$84.82M1.694,377 shs111,553 shs
AlloVir, Inc. stock logo
ALVR
AlloVir
$4.03
-1.7%		$4.19
$7.96
▼
$24.15
$20.32M0.6315,685 shs52,613 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.67
+7.7%		$1.56
$1.34
▼
$3.20
$87.64M0.0467,500 shs135,390 shs
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
$1.14
-4.2%		$1.18
$0.89
▼
$2.09
$78.40M-0.2454,854 shs36,957 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
0.00%-1.41%0.00%-2.69%-25.06%
AlloVir, Inc. stock logo
ALVR
AlloVir
-1.71%-2.89%+18.53%-23.53%+57.42%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%+8.44%+0.60%-2.62%-26.11%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
0.00%+0.88%-8.80%-12.31%-22.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
2.75
Moderate Buy$46.80416.56% Upside
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.40
Hold$5.67239.32% Upside
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest ALVR, ACET, OKYO, and TELO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/6/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$100.00 ➝ $90.00
7/17/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$7.00 ➝ $5.00
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
N/AN/AN/AN/A$12.83 per shareN/A
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A$0.30 per shareN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/A$0.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
-$116.80M-$11.45N/AN/AN/AN/A-74.90%-60.87%11/11/2026 (Estimated)
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$8.95MN/AN/AN/AN/AN/AN/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$10.41M-$0.91N/AN/AN/AN/A-102.70%-90.75%9/2/2026 (Estimated)

Latest ALVR, ACET, OKYO, and TELO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026N/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.07N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.07-$0.79-$0.72-$0.79N/AN/A
8/5/2026Q2 2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
-$1.69-$1.99-$0.30-$1.99N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
N/AN/AN/AN/AN/A
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
0.01
6.71
6.71
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
2.43
2.43
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
16.16
16.16

Institutional Ownership

CompanyInstitutional Ownership
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
83.89%
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
3.40%
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
16.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
909.36 million9.04 millionOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionNo Data
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
752.48 million31.25 millionNot Optionable
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
168.78 million57.52 millionN/A

Recent News About These Companies

Telomir Pharmaceuticals (TELO) Expected to Announce Quarterly Earnings on Wednesday
August 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30983408
Telomir Pharmaceuticals (TELO) to Post Quarterly Earnings on Wednesday
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-telomir-pharmaceuticals-telo-to-post-quarterly-earnings-on-wednesday-2026-08-26/
Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telomir-pharmaceuticals-nasdaqtelo-releases-quarterly-earnings-results-2026-08-13/
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?
August 12, 2026  |  defenseworld.netD
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% - Should You Sell?
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telomir-pharmaceuticals-nasdaqtelo-stock-price-down-34-should-you-sell-2026-08-12/
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/telomir-announces-peer-reviewed-publication-demonstrating-telomir-zn-suppresses-tumor-growth-in-tnbc-and-prostate-cancer-models-1036435451
Telomir-Zn Preclinical Data Support Advancement in TNBC
August 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-zn-preclinical-data-support-advancement-in-tnbc?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models
August 10, 2026  |  quiverquant.comQ
TELO Telomir Pharmaceuticals, Inc.
July 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/TELO
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...
June 15, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/34770/telomir-pharmaceuticals-announces-peer-reviewed-publication-in-biomedicine-pharmacotherapy-demonstrating-restoration-of-insulin-sensitivity-with-telomir-zn-in-a-preclinical-type-2-diabetes-model/
Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data
June 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-showcases-preclinical-telomir-zn-diabetes-efficacy-data?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
June 15, 2026  |  accessnewswire.comA
Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change
June 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Inc TELO
May 26, 2026  |  morningstar.comM
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease
May 20, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/32948/telomir-pharmaceuticals-reports-peer-reviewed-publication-of-telomir-zn-data-demonstrating-improved-survival-and-multiple-endpoint-benefits-in-wilsons-disease/
Telomir-Zn Preclinical Data Published in Wilson’s Disease
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-zn-preclinical-data-published-in-wilsons-disease?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
May 20, 2026  |  accessnewswire.comA
Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn
April 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-receives-fda-ind-clearance-for-telomir-zn?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
April 30, 2026  |  accessnewswire.comA
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
April 24, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/31216/telomir-pharmaceuticals-completes-acquisition-of-teli-pharmaceuticals-securing-global-rights-to-telomir-1-telomir-zn/
Telomir Pharmaceuticals Inc.
April 2, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/telo/research-ratings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adicet Bio stock logo

Adicet Bio NASDAQ:ACET

$9.06 +0.05 (+0.55%)
As of 08/28/2026 04:00 PM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

AlloVir stock logo

AlloVir NASDAQ:ALVR

$4.03 -0.07 (-1.71%)
As of 08/28/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$1.67 +0.12 (+7.74%)
As of 08/28/2026 04:00 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Telomir Pharmaceuticals stock logo

Telomir Pharmaceuticals NASDAQ:TELO

$1.14 -0.05 (-4.20%)
As of 08/28/2026 04:00 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas